Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06432881 · ClinicalTrials.gov registry record · NA
Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE)
A NA study of Hypoxemia, sponsored by Masimo Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT06432881: Recruiting NA study of Hypoxemia, sponsored by Masimo Corporation.
NCT06432881 is a NA study of Hypoxemia that is actively recruiting participants, run by Masimo Corporation. The registered enrollment target is 152 participants, below the 480-participant average among 10 other Hypoxemia trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06432881, a NA study of Hypoxemia, is actively recruiting participants, sponsored by Masimo Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the performance of Masimo RD SET® SpO2 sensors in subjects with light and dark skin pigmentation in the intensive care therapeutic area.
Primary Outcome
The study is designed to evaluate the performance of Masimo RD SET SpO2 sensors in subjects with light and dark skin pigmentation in the intensive care therapeutic area. SpO2 accuracy will be determined by calculating the ARMS value which will be reported as percent of oxygen saturated hemoglobin.
Conditions Studied
Interventions
- DEVICE RD SET Sensor
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2024-01-08 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What NCT06432881 shows while recruiting
NCT06432881 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 480-participant average among 10 other Hypoxemia trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Hypoxemia appearing as the primary indexed condition, and to 1 intervention - of which RD SET Sensor is the first listed.
NCT06432881 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT06432881 about?
NCT06432881 is a clinical study titled "Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE)". The objective of this study is to evaluate the performance of Masimo RD SET® SpO2 sensors in subjects with light and dark skin pigmentation in the intensive care therapeutic area.
What is the current status of trial NCT06432881?
This trial is currently recruiting. It is a NA study. The enrollment target is 152 participants. The study started on 2024-01-08. Estimated completion is 2026-03-01.
What conditions does trial NCT06432881 study?
This clinical trial studies the following conditions: Hypoxemia.
What interventions are being tested in trial NCT06432881?
The interventions under investigation include: RD SET Sensor (DEVICE).
Who is sponsoring clinical trial NCT06432881?
This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06432881 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoxemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06432881's enrollment target sits among peer trials
152 4th of 10 higher than 7 of 10 other Hypoxemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoxemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
RECRUITING · NA
-
Rebreathing-induced Hypoxia and Glucose Levels
ACTIVE NOT RECRUITING · NA
-
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
COMPLETED · NA
-
Pulse Oximetry With Automated Verbal Prompts
COMPLETED · NA
-
Nasotracheal Intubation With VL vs DL in Infants Trial
COMPLETED · NA
-
Postoperative Respiratory and Activity Monitoring
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI